Effect of a food-derived isoquercitrin supplement on plasma uric acid and other metabolic markers: A randomised, double-blinded, placebo-controlled, cross-over trial in healthy adults

开始日期2024-05-08

申办/合作机构

Monash University

JPRN-UMIN000046945 / CompletedIIT

A randomized, double-blind, placebo-controlled study to evaluate the efficacy of the continuous intake of food containing quercetin glycoside on the SARS-CoV-2 vaccine efficacy in a healthy adult with a high body-mass index or elderly. - A study to evaluate the efficacy of food intake containing quercetin glycoside on the SARS-CoV-2 vaccine efficacy.

开始日期2022-03-15

申办/合作机构

Hokkaido Information University

NCT04536090 / Unknown status临床2期IIT

An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)

This is an open-label, randomized, multi-centre study where hospitalized subjects will be randomized in a 2:1 ratio to receive Isoquercetin (IQC-950AN) in addition to standard of care or standard of care only for 28 days following confirmation of a COVID-19 infection.

开始日期2022-01-01

申办/合作机构

Institut de recherches cliniques de Montréal

[+3]

100 项与异槲皮素相关的临床结果

登录后查看更多信息

100 项与异槲皮素相关的转化医学

登录后查看更多信息

100 项与异槲皮素相关的专利（医药）

登录后查看更多信息

1,576

项与异槲皮素相关的文献（医药）

2025-01-01·Journal of Ethnopharmacology

Bioguided isolation of anti-inflammatory and anti-urolithiatic active compounds from the decoction of Cissus gongylodes leaves

Article

作者: Chagas-Paula, Daniela A. ; Soares, Marisi G. ; Costa, Lara P D M ; Costa, Lara P.D.M. ; Murgu, Michael ; Silva, Paulo R S ; Salem, Paula P.O. ; Nicácio, Karen J. ; Silva, Daniele O. ; Dias, Danielle F. ; Paula, Ana Claudia Chagas de ; Salem, Paula P O ; Dias, Danielle F ; Soares, Marisi G ; Nicácio, Karen J ; Leite, Fernanda Brito ; Caldas, Ivo S ; Caldas, Ivo S. ; Chagas-Paula, Daniela A ; Silva, Paulo R.S. ; Silva, Daniele O

ETHNOPHARMACOLOGICAL RELEVANCEThe Cissus gongylodes has traditionally been used in the diet of indigenous people in Brazil and in traditional medicine for kidney stone removal and inflammatory diseases. The active compounds responsible for these pharmacological activities are unknown.AIM OF THE STUDYThis study aims to isolate, for the first time, the compounds in the decoction of C. gongylodes leaves responsible for their anti-inflammatory and anti-urolithiatic ethnopharmacological properties.MATERIALS AND METHODSThe most active fractions of the C. gongylodes leaf decoction were fractionated using SPE-C18 and the compounds were purified through HPLC-UV-DAD. The decoction fractions and isolated compounds were evaluated for their anti-inflammatory and anti-urolithiatic activities. The anti-inflammatory activity was assessed using an ex vivo assay in human blood induced by LPS and calcium ionophore, measuring inflammatory mediators, PGE2 and LTB4. The anti-urolithiatic activity was evaluated using an in vitro experimental model with human urine to determine the dissolution of the most recurrent calcium oxalate (CaOx) crystals. Additionally, the decoction was chemically characterized through metabolomic analysis using UHPLC-ESI-HRMS.RESULTSThe isolated compounds from the decoction of C. gongylodes, including rutin, eriodictyol 3'-O-glycoside, and isoquercetin, have demonstrated significant multi-target actions. These components act as anti-inflammatory agents by inhibiting the release of main inflammatory mediators, PGE2 and LTB4. Additionally, they exhibit anti-urolithiatic properties, promoting the dissolution of calcium oxalate (CaOx) crystals. Furthermore, the characterization of the decoction by UHPLC-ESI-HRMS revealed a high content of flavonoids, mainly glycosylated flavonoids.CONCLUSIONSThe results support the traditional use of C. gongylodes decoction, identifying the compounds responsible for its anti-inflammatory and anti-urolithiatic effects. The decoction fractions and isolated compounds exhibited dual anti-inflammatory activity, effectively inhibiting key inflammatory pathways and potentially presenting fewer adverse effects while also promoting the dissolution of CaOx crystals associated with urolithiasis. The multi-target action displayed by C. gongylodes is particularly desirable in the treatment of urolithiasis, as inflammation and PGE2 production precede and contribute to the formation of CaOx crystals in the kidneys. Based on these actions, C. gongylodes emerges as a potent source of active compounds for the development of new treatments for urolithiasis.

2025-01-01·Journal of Ethnopharmacology

A strategy of Q-markers identification based on effect, property flavour material basis and rapid quantitative evaluation via near-infrared spectroscopy and chemometric methods for the quality control of Flos Trollii (FT)

Article

作者: Du, Qing-Yu ; Zhu, Xiu-Zhen ; Zhou, Xin ; Mao, Shan ; Sun, Lei ; Zhang, Xia ; He, Min ; Shi, Jie ; Yu, Yong-Jie

ETHNOPHARMACOLOGICAL RELEVANCEFlos Trollii (FT) is the dried flower of Trollius Chinensis Bunge of Ranunculaceae with the pharmacological properties of anti-inflammatory, antibacterial, antiviral, anti-oxidative. The herb FT is not only a traditional Chinese medicine (TCM) but also an extensively utilized ethnic medicine, employed by diverse ethnic groups including Mongolian, Tibetan, and Kazakh.AIM OF STUDYFT was taken as an example to construct a strategy of quality markers (Q-markers) identification based on effect, property flavor material basis, and rapid quantitative evaluation using near-infrared (NIR) spectroscopy and chemometric methods of TCM.MATERIALS AND METHODSInitially, the anti-inflammatory efficacy of FT from three places of origin was evaluated using the RAW264.7-cell inflammatory model, and the bitter property flavor was characterized using an electronic tongue. The high-performance liquid chromatography(HPLC) fingerprint of FT was generated, and the quality of FT from different origins was evaluated employing chemometrics. Next, potential anti-inflammatory and bitter property flavor compounds were screened utilizing a fingerprinting-effect relationship and fingerprinting-property flavor relationship model using partial least squares regression (PLSR). The Q-markers of the FT were confirmed based on the testability principle. Then, a swift, uncomplicated, and precise Q-marker content of the FT prediction model was developed by adopting NIR.RESULTSThe main common fingerprinting peaks affecting FT's efficacy and property flavor were screened. Five of these compounds, 2″-O-beta-L-galactopyranosylorientin, orientin, vitexin, veratric acid, and isoquercitrin, characterized using HPLC and ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS), could be regarded as Q-markers of FT. Q-marker content of the FT prediction model developed adopting NIR spectroscopy was rapid and effective.CONCLUSIONAccording to the strategy proposed in this study, a quantitative NIR spectroscopic method to identify Q-markers could be a tool to improve the QC efficiency of TCM.

2024-12-01·Journal of Ethnopharmacology

Elucidation of anti-pneumonia pharmacodynamic material basis and potential mechanisms of Xiebai San by combining spectrum–efficacy relationship and surface plasmon resonance

Article

作者: Liu, An ; Su, Jiangmin ; Xu, Qingxia ; Liu, Xianju ; Jiang, Liang ; Zhang, Jun ; Liu, Li ; Guo, Cong ; Cheng, Jintang ; Liu, Yan ; Chen, Chang ; Jiang, Jinzhu ; Wang, Lianmei ; Chen, Sha ; Zhao, Anyi ; Di, Jipeng

ETHNOPHARMACOLOGICAL RELEVANCEXiebai San (XBS), a classic Chinese prescription, has been used for the clinical treatment of pneumonia-related diseases for thousands of years. However, the anti-pneumonia pharmacodynamic material basis of XBS and its underlying mechanisms remain unclear.AIM OF THE STUDYThis study aimed to comprehensively investigate and verify the anti-pneumonia pharmacodynamic material basis and mechanisms of XBS.MATERIALS AND METHODSThis study explored the anti-pneumonia activity and key pneumonia targets of XBS in lipopolysaccharide (LPS)-induced zebrafish and RAW264.7 cells in vivo and in vitro through transcriptomics, western blotting, and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The chemical fingerprint of XBS was established using high-performance liquid chromatography, and the similarities and areas of characteristic peaks of 15 batches of XBS were analyzed. Based on the spectrum-efficacy relationship, the potential anti-inflammatory components were screened according to their peak areas and efficacy using principal component analysis (PCA), bivariate correlation, and partial least squares regression analysis. Active components that bind to core targets were further screened based on surface plasmon resonance (SPR). The binding mode of proteins and components was simulated via molecular docking, which enabled the identification of the primary active components of XBS, thereby elucidating its anti-pneumonia properties. Finally, the anti-inflammatory activities of these components were verified in vitro.RESULTSXBS decreased neutrophil aggregation in zebrafish and nitric oxide (NO) secretion in RAW264.7 cells as well as suppressed the release of downstream inflammatory cytokines such as iNOS, TNF-α, IL-1β, IL-18, and CXCL10 related to TNF and JAK-STAT signaling pathways. The phosphorylation of IκBα, Akt, and Stat3 was alleviated after XBS in cells. The fingerprint similarities of 15 batches of XBS ranged from 0.381 to 0.994, with a large difference. A total of 15 characteristic peaks were identified, and the relative standard deviation of their peak areas ranged from 24.1% to 70.7%. The results of in vitro anti-inflammatory activities of 15 batches of XBS showed that all samples inhibited the expression levels of NO and nine inflammatory markers. The anti-inflammatory index of 15 batches of XBS was determined to be 0.69-0.96 based on transformation of the anti-inflammatory rate and composite index method via PCA. The spectrum-efficacy relationship model of 15 characteristic peak areas and the anti-inflammatory index showed that 7 main potential active components were related to the anti-inflammatory activity of XBS. Moreover, four components (mulberroside A, isoquercitrin, liquiritigenin, and glycyrrhizic acid) screened based on SPR had different affinities toward TNFR1, Akt1, and Stat3 proteins, and the binding modes were elucidated via molecular docking. Finally, in LPS-induced RAW264.7 cells, all four active components (at a concentration of 60 μM) significantly inhibited the expression levels of NO and inflammatory markers.CONCLUSIONSBased on the comprehensive strategy of spectrum-efficacy relationship and SPR, mulberroside A, isoquercitrin, liquiritigenin, and glycyrrhizic acid were identified as the primary pharmacodynamic active components involved in the anti-pneumonia activity of XBS and were found to intervene in TNF and JAK-STAT signaling pathways.

项与异槲皮素相关的新闻（医药）

2024-07-08

·BioSpace

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This randomized (1:1), open-label, phase 2 study (AB20001) was designed to evaluate the safety and efficacy of masitinib plus isoquercetin in hospitalized patients with moderate COVID-19 (WHO 7-point ordinal scale level 4) or severe COVID-19 (level 5). The study initially planned to recruit 200 patients (over 18 years of age with no upper age limit). The primary objective was to improve the clinical status of patients after 15 days of treatment, as measured by the WHO 7-point ordinal scale. Following a DSMB recommendation, decision was taken to continue the study only in level 4 patients (i.e. hospitalized patients with oxygen supply <6 L/min with SpO2 maintained ≥92%). The study could not recruit the planned 200 patients. The decision was therefore taken to stop inclusion after 95 patients were randomized. The objective was to detect a trending treatment effect with 95 patients that would translate into a significant effect when simulating the same effect with the planned enrolment of 200 patients. If this objective was reached, then the conclusion would be that it is worth continuing to evaluate masitinib as an agent in the treatment of covid in patients hospitalized with moderate need of oxygen. The study showed an odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. Sensitivity analyses at day 12, 13 and 14 with 95 patients recruited displayed a p-value of respectively p=0.016, 0.019, 0.018 and odds ratio 3.2, 3.2 and 3.4. This was due to improvement of certain placebo patients at day 15 but not before. The safety was in line with the known safety pro masitinib. Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France said: “This result confirms the anti-inflammatory activity of masitinib, by controlling activated macrophages and mast cells involved in COVID. In addition, several publications highlighted the capacity of masitinib to act as an indirect broad antiviral agent against COVID. With this result, masitinib can be considered a drug of choice to be evaluated in the context of a future pandemic”. Alain Moussy, co-founder and CEO of AB Science said: “We are thankful to the European Investment Bank for having funded this development of masitinib in COVID, and to our partner Quercegen for having proposed to combine masitinib with isoquercetin. This result warrants further evaluation and we will discuss such opportunity with public entities or private partners”. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science’s website: . Forward-looking Statements - AB Science This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations investors@ab-science.com Attachment CP Covid Results vENG VF

临床2期临床结果

2023-01-13

·生物谷

Genes Environ：软枣猕猴桃果汁有望用于预防和减少肺癌

肺癌是日本和全球的一个主要死因，在所有癌症中，肺癌是五年生存率最低的癌症之一。在临床上，科学家们已证实多种水果中的活性成分可将包括癌症在内的慢性疾病风险降至最低。在一项新的研究中，日本冈山大学药学系副教授Sakae Arimoto-Kobayashi博士及其团队利用小鼠模型发现，软枣猕猴桃（Actinidia arguta）果汁及其组成成分异槲皮素（isoquercetin）有助于预防和减少肺癌。相关研究结果近期发表在Genes and Environment期刊上，论文标题为“Chemopreventive effects and anti-tumorigenic mechanisms of Actinidia arguta, known as sarunashi in Japan toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)- induced lung tumorigenesis in a/J mouse”。软枣猕猴桃是富含多酚和维生素C的植物之一。之前，Arimoto-Kobayashi团队已证实软枣猕猴桃果汁对诱变、炎症和小鼠皮肤肿瘤发生的抑制作用。他们已确定了软枣猕猴桃中负责抗诱变作用的成分是水溶性和热敏性的酚类化合物。随后，他们提出多酚化合物异槲皮素是具有抗致癌潜力的组成成分。Arimoto-Kobayashi博士解释说，“在这项新的研究中，我们试图研究软枣猕猴桃果汁及其组成成分异槲皮素对4-(甲基亚硝胺)-1-(3-吡啶基)-1-丁酮（NNK）诱导的A/J小鼠肺部肿瘤发生的化学预防作用，并确定软枣猕猴桃抗肿瘤作用的潜在机制。”为此，这些作者用NNK诱导小鼠体内的肿瘤生长，其中NNK是烟草产品中存在的一种已知的致癌化合物。利用一系列的实验和对照，他们研究了软枣猕猴桃果汁和异槲皮素对小鼠肺部肿瘤发生的影响。他们的实验结果是令人鼓舞的：在接受NNK注射和口服软枣猕猴桃果汁的小鼠组中，每只小鼠肺部的肿瘤结节数量明显低于仅注射NNK的小鼠组。此外，口服异槲皮素也减少了小鼠肺部的肿瘤结节数量。在A/J小鼠30周龄时NNK诱导的肺损害(I组)。图片来自Genes and Environment, 2023, doi:10.1186/s41021-022-00255-0。接下来，该团队在发现潜在的作用机制方面取得了突破性进展。NNK和1-甲基-3-硝基-1-亚硝基胍（MNNG）是已知的诱变剂，即引发DNA突变的试剂。因此，他们设计了一系列实验，利用伤寒沙门氏菌TA1535---一种通常用于检测DNA突变的细菌菌株，研究了软枣猕猴桃果汁和异槲皮素对NNK和MNNG介导的诱变的影响。正如预期的那样，使用伤寒沙门氏菌TA1535检测的NNK和MNNG的致突变性在软枣猕猴桃果汁的存在下有所下降。然而，当使用伤寒沙门氏菌YG7108（一种缺乏负责DNA修复的关键酶的菌株）进行类似测试时，软枣猕猴桃果汁无法减少NNK和MNNG的诱变作用。基于这一关键观察，这些作者得出结论，软枣猕猴桃果汁似乎是通过加快DNA修复来介导它的抗诱变作用。最后，利用基于细胞的实验，该团队还发现软枣猕猴桃果汁抑制了Akt 的作用，其中Akt是一种参与癌症信号传导的关键蛋白。众所周知，Akt和一种名为PI3k 的相关蛋白在几种人类癌症中被过度激活。论文共同作者、冈山大学附属医院过敏与呼吸医学系教授Katsuyuki Kiura说，“软枣猕猴桃果汁和异槲皮素减少了NNK诱导的肺部肿瘤发生。软枣猕猴桃果汁靶向致癌过程中的起始和生长或进展步骤，特别是通过抗诱变作用，刺激烷基DNA加合物修复，以及抑制Akt介导的生长信号传导。异槲皮素可能通过抑制Akt的磷酸化对软枣猕猴桃果汁的生物效应有部分贡献，但它可能不是主要的活性成分。”总之，这项新的研究显示，小鼠口服软枣猕猴桃果汁后，肺部肿瘤发生得到了抑制。尽管需要进行临床试验，但是软枣猕猴桃果汁的组成成分，包括isoQ，似乎是很好的预防候选化合物。参考资料：Jun Takata et al. Chemopreventive effects and anti-tumorigenic mechanisms of Actinidia arguta, known as sarunashi in Japan toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)- induced lung tumorigenesis in a/J mouse. Genes and Environment, 2023, doi:10.1186/s41021-022-00255-0.

临床研究

2023-01-04

·Science Daily

Actinidia arguta (sarunashi) juice inhibits lung cancer in mice, study finds

A research team has shown that Sarunashi juice and its constituting component isoquercetin help prevent and reduce lung cancer in laboratory mice. Among all the cancers, lung cancer has one of the lowest five-year survival rates. Smoking tobacco and using tobacco-based products is known to heavily contribute to the development of lung cancer. It is a clinically established fact that the active ingredients in various fruits minimize the risk of chronic diseases including cancer. "Sarunashi" (Actinidia arguta) is an edible fruit cultivated in Japan's Okayama Prefecture. Using a mouse model, researchers from Okayama University led by Dr. Sakae Arimoto Kobayashi, Associate Professor in the Faculty of Pharmaceutical Sciences, Okayama University, have shown that Sarunashi juice and its constituting component isoquercetin (isoQ) help prevent and reduce lung cancer. A. arguta is one of the richest sources of polyphenols and vitamin C. Previously, the researchers had demonstrated the inhibitory effect of Sarunashi juice (sar-j) on mutagenesis, inflammation, and mouse skin tumorigenesis. They had identified the components of A. arguta responsible for the anti-mutagenic effects as water-soluble and heat-sensitive phenolic compounds. Subsequently, the researchers proposed the polyphenolic compound isoQ as a constituting component with anticarcinogenic potential. Dr. Arimoto Kobayashi explains, "In this study, we sought to investigate the chemo-preventive effects of A. arguta juice and its constituting component isoQ on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J mice, and identify the possible mechanisms underlying the anti-tumorigenic effects of A. arguta." To this end, the team induced tumor growth in mice using NNK, a known cancer-causing compound present in tobacco products. Using a series of experiments and controls, the team studied the effects of sar-j and isoQ on lung tumorigenesis in mice. The results were encouraging: The number of tumor nodules per mouse lung in the group that received NNK injections and oral doses of A. arguta juice was significantly lower than that in the group injected with NNK only. Moreover, the oral administration of isoQ also reduced the number of nodules in the mouse lungs. Next, the team broke ground by discovering the likely mechanism of action. NNK and 1-methyl-3-nitro-1-nitrosoguanidine or "MNNG" are known mutagens -- agents that trigger DNA mutations. The team therefore designed a series of experiments to study the effect of sar-j and isoQ on NNK- and MNNG-mediated mutagenesis using Salmonella typhimurium TA1535 -- a bacterial strain commonly used for detecting DNA mutations. As expected, the mutagenicity of NNK and MNNG detected using S. typhimurium TA1535 decreased in the presence of sar-j. However, when similar tests were conducted using S. typhimurium YG7108, a strain lacking key enzymes responsible for DNA repair, sar-j was unable to decrease the mutagenic effects of NNK and MNNG. Based on this critical observation, the researchers concluded that sar-j seems to mediate its antimutagenic effect by accelerating DNA repair. Finally, using cell-based experiments, the team also showed that sar-j suppressed the action of "Akt," a key protein involved in cancer signaling. It is a known fact that Akt and an associated protein called "PI3k," get over-activated in several human cancers. Co-author Katsuyuki Kiura, a Professor in the Department of Allergy and Respiratory Medicine, Okayama University Hospital, muses, "Sar-j and isoQ reduced NNK-induced lung tumorigenesis. Sar-j targets both the initiation and growth or progression steps during carcinogenesis, specifically via anti-mutagenesis, stimulation of alkyl DNA adduct repair, and suppression of Akt-mediated growth signaling. IsoQ might contribute in part to the biological effects of sar-j via suppression of Akt phosphorylation, but it may not be the main active ingredient." Their findings were published on 9 December 2022 in Genes and Environment. In summary, the study shows that lung tumorigenesis in mice was suppressed following the oral intake of sar-j. Although clinical trials are warranted, the constituting components of sar-j, including isoQ, seem to be attractive candidates for chemoprevention.

临床结果

100 项与异槲皮素相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾细胞癌	临床1期	意大利	Quercegen Pharmaceuticals LLC	2016-11-01
结直肠癌	临床1期	美国	Quercegen Pharmaceuticals LLC	2015-01-01
非小细胞肺癌	临床1期	美国	Quercegen Pharmaceuticals LLC	2015-01-01
胰腺癌	临床1期	美国	Quercegen Pharmaceuticals LLC	2015-01-01
血栓形成	临床1期	美国	Quercegen Pharmaceuticals LLC	2015-01-01
静脉血栓栓塞	临床1期	美国	Quercegen Pharmaceuticals LLC	2015-01-01
肺损伤	临床前	中国台湾	中山医学大学	2024-03-04
镰状细胞血症	临床前	-	Quercegen Pharmaceuticals LLC	2020-12-01
β地中海贫血	临床前	-	Quercegen Pharmaceuticals LLC	2020-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04622865 (Biospace) 人工标引	临床2期	新型冠状病毒感染	95	masitinib + Isoquercetin + Best Supportive Care	(襯窪構築選鑰積鬱憲夢) = odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. 醖鹹遞網觸餘鑰鬱壓築 (繭醖範獵網願選簾鑰壓 ) 更多	积极	2024-07-08
				Best Supportive Care
NCT04514510 (CTgov)	临床2期	镰状细胞血症	46	Isoquercetin (Participants With Sickle Cell Disease Receiving Isoquercetin)	鑰獵遞窪壓齋齋鬱壓網(選選構繭醖鹽醖鏇積鬱) = 積鏇繭範餘艱鏇觸鏇齋築簾築選膚鹹顧鑰廠繭 (築選淵繭壓醖襯壓積窪, 鏇窪觸鹹襯襯艱範顧衊 ~ 淵夢壓衊獵齋鏇觸簾醖) 更多	-	2023-06-27
				Placebo (Participants With Sickle Cell Disease Receiving Placebo)	鑰獵遞窪壓齋齋鬱壓網(選選構繭醖鹽醖鏇積鬱) = 範遞壓繭願顧艱蓋繭餘築簾築選膚鹹顧鑰廠繭 (築選淵繭壓醖襯壓積窪, 顧範蓋淵衊選鏇糧壓蓋 ~ 網鬱鏇網網觸憲鑰衊鹹) 更多
NCT01722669 (PK/PD, CTgov)	早期临床1期	血栓形成倾向	38	Quercetin (Quercetin 500 mg (ARM A1))	網製襯憲網鏇鹹選構醖(鏇淵膚範窪鑰衊鬱繭鏇) = 網觸醖艱齋範繭淵鹹膚餘廠願艱憲製醖製衊鑰 (築鏇觸廠衊廠遞製鹽獵, 壓襯蓋醖簾窪繭構鑰鹹 ~ 鹽醖鹹襯鹹繭淵餘壓網) 更多	-	2020-10-12
				Isoquercetin (Isoquercetin 500 mg (ARM B1))	網製襯憲網鏇鹹選構醖(鏇淵膚範窪鑰衊鬱繭鏇) = 築窪觸鬱醖廠蓋鹽壓觸餘廠願艱憲製醖製衊鑰 (築鏇觸廠衊廠遞製鹽獵, 餘願襯鏇鹹製鹹鏇憲膚 ~ 繭憲選醖衊鬱築醖襯願) 更多
NCT02195232 (CATIQ, CTgov)	临床2/3期	血栓形成 \| 非小细胞肺癌 \| 结直肠癌 \| 胰腺癌 \| 静脉血栓栓塞	64	Isoquercetin (Cohort A - Isoquercetin)	願網蓋膚鬱齋構壓選鹽(衊糧蓋範鬱淵獵繭艱範) = 鏇襯鬱襯鹽鹽憲積繭窪窪鬱繭網鹹襯鏇鏇觸構 (築鬱顧鏇夢齋築鏇顧遞, 網鑰餘繭憲觸艱繭鬱積 ~ 齋餘憲齋簾遞膚繭糧糧)	-	2019-11-12
				Isoquercetin (Cohort B - Isoquercetin)	願網蓋膚鬱齋構壓選鹽(衊糧蓋範鬱淵獵繭艱範) = 廠觸築窪蓋鹽選襯襯襯窪鬱繭網鹹襯鏇鏇觸構 (築鬱顧鏇夢齋築鏇顧遞, 夢醖鹹築簾膚鏇糧憲鹹 ~ 衊網網醖簾鬱製選醖襯)
NICE trial (ASN2019)	N/A	内皮功能障碍 vWF \| IL-17 \| vascular adhesion molecule-1 ... 更多	70	Sodium nitrite + Isoquercetin	膚窪齋衊廠憲淵積膚鑰(網鬱窪夢積壓夢醖製製) = 鑰憲獵憲鹽獵糧築願壓鬱蓋獵壓壓鹹糧艱遞積 (醖糧鑰餘築廠鏇膚憲壓, -0.07 ~ 2.32)	积极	2019-11-05
				Placebo	膚窪齋衊廠憲淵積膚鑰(網鬱窪夢積壓夢醖製製) = 膚襯構壓構鑰網鏇夢願鬱蓋獵壓壓鹹糧艱遞積 (醖糧鑰餘築廠鏇膚憲壓, -0.86 ~ 1.53) 更多
NCT02195232 (Pubmed \| JCI Insight)	临床2期	晚期癌症	64	Isoquercetin 500 mg	壓醖獵齋鑰糧鏇蓋醖顧(鹹襯鹽艱膚鑰鏇鬱淵鏇) = 窪糧淵醖製構遞艱夢遞鹹壓願壓獵製繭壓衊餘 (鏇淵願製艱製築夢鑰夢 )	-	2019-02-21
				Isoquercetin 1000 mg	壓醖獵齋鑰糧鏇蓋醖顧(鹹襯鹽艱膚鑰鏇鬱淵鏇) = 顧醖襯構齋醖鹹遞餘廠鹹壓願壓獵製繭壓衊餘 (鏇淵願製艱製築夢鑰夢 ) 更多